Global Antibacterial Drugs Market 2017-2027

LONDON, March 20, 2017 /PRNewswire/ --

Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others

The global antibacterial drugs market is expected to grow at a CAGR of 1.3% in the first half of the forecast period and a CAGR of 3.1% in the second half of the forecast period. The market is estimated at $41.76bn in 2016 and $44.54bn in 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 304-page report you will receive 124 tables and 97 figures - all unavailable elsewhere.

The 304-page report provides clear detailed insight into the global antibacterial drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Global Antibacterial Drugs Market forecasts from 2017-2027

• Revenue forecasts for the 6 leading submarkets from 2017-2027:
- Cephalosporins
- Penicillins
- Fluoroquinolones
- Macrolides
- Carbapenems
- Others

• Revenue forecasts for the 43 leading marketed antibacterial drugs from 2017-2027:
- Cephalosporins: Rocephin, Sulperazon, Ceftin/Zinnat, Meiact, Flomox, Teflaro, Zeftera, Ceftolozane-tazobactam, Ceftazidime-Avibactam
- Penicillins: Generic amoxicillin, Augmentin, Zosyn/Tazocin, Unasyn, Generic amoxicllin-clavulanic acid, Amoxil
- Fluoroquinolones: Avelox, Cravit, Vigamox, Ciprodex, Cipro/Ciprobay, Geninax, Defafloxacin
- Macrolides: Biaxin/Clarith, Zithromax, Dalacin, Dificid, Solithromycin
- Carbapenems: Invanz, Merrem/Meropen, Primaxin, Doribax
- Other antibacterial drugs: Zyvox, Cubicin, Tygacil, TOBI/TIP, Solodyn, Vibativ, Sirturo, Tedizolid, Oritavancin, Dalbavancin, Nemonoxacin, Surotomycin

To see a report overview please email Sara Peerun on [email protected]

• Revenue forecasts for the leading developed and emerging national and regional markets. Markets forecasted in this report are the following:
- The US
- The EU: France, Germany, Italy, Spain, the UK, and others
- Japan
- The BRIC countries: Brazil, Russia, India, China
- South Korea
- The Rest of the World

• Analysis of the strengths, weaknesses as well as the opportunities and threats of the antibacterial drugs industry and market

• Coverage of antibacterial drug candidates in the R&D pipeline. Discussions of research and development - see progress in this industry, finding technological, clinical and commercial outlooks and opportunities

Visiongain's study is intended for anyone requiring commercial analyses for the Global Antibacterial Drugs Market. You find data, trends and predictions.

Buy our report today Global Antibacterial Drugs Market 2017-2027: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others.

To request a report overview of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100

Or click on: https://www.visiongain.com/Report/1821/Global-Antibacterial-Drugs-Market-2017-2027

Companies Mentioned 

Abbott Laboratories

AbbVie

Achaogen

Actavis

Actelion

Affinium Pharmaceutical

AiCuris GmbH & Co. KG

Alcon

Alkem Laboratories

Allergan

Allied Pharma

Apotex

APP Pharmaceuticals

Aptalis Pharma

Aquapharm Biodiscovery

Aradigm

Aridis Pharmaceuticals

Ascend Therapeutics

Astellas Pharma

AstraZeneca

Aurobindo Pharma

Barr Pharmaceuticals

Basilea Pharmaceuticals

Bayer Laboratories

Biomax Biotechnics

Bristol-Myers Squibb

Cadila Healthcare

Calixa Therapeutics

Cardeas Pharma

Cellceutix

Cempra Pharmaceuticals

Cipla

Claris Lifesciences

Cornerstone Biopharma

Cornerstone Therapeutics

Corona Remedies

Critical Therapeutics

Cubist Pharmaceuticals

Daiichi Sankyo

Dainippon Sumitomo

Discuva

Dr. Reddy's Laboratories

Durata Therapeutics

Eli Lilly

Emcure Pharmaceuticals

Eros Pharma

Forest Laboratories

Furiex Pharmaceuticals

Gate Pharma

Gilead Sciences

Glenmark

GlycoVaxyn

GlaxoSmithKline (GSK)

Hetero

Hi-Tech Pharma

Hikma Farmaceutica

Hospira

Insmed

Intercell

Itochu Chemical Frontier

Janssen Pharmaceuticals

Johnson & Johnson

KaloBios

Kenta Biotech

Kuhnil Pharm

Lupin

Macleod Pharmaceuticals

Medicis

MedImmune

Meiji

Melinta Therapeutics

Merck & Co.

Merlion Pharmaceuticals

Microlabs

MicuRx Pharmaceuticals

Mpex Pharmaceuticals

Mylan

Nabriva Therapeutics

Nalneva

Neiss Labs

Nektar Therapeutics

Novacta Biosystems

Novartis

Novexel

Optimer Biotechnology

Orchid Chemicals

Orchid Healthcare

Ortho-McNeil

Paratek Pharmaceuticals

Peninsula Pharmaceuticals

Pfizer

Pharmacia

Phico Therapeutics

Piramal Healthcare

Plenus Pharmaceuticals

Pliva

Polyphor

Procarta Biosystems

Procter & Gamble Pharmaceuticals

Ranbaxy

Redx Pharma

Roche

Roxane

R-Pharma

Sagent Pharmaceuticals

Sandoz

Sanofi

Savara Pharmaceuticals

Sawai Pharmaceutical

Schering Plough

Seika Pharma

Sequella

Shanghai MengKe Pharmaceuticals

Shionogi

Shire

Sidmak Labs

Solitaire Pharmacia

Specialised Therapeutics Australia

Sunovion Pharma

TaiGen Biotechnology

Taisho Toyama

Takeda

TAP Holdings

Targanta Therapeutics

Tetraphase Pharmaceuticals

Teva Pharmaceutical Industries

The Medicines Company

Theravance

Torrent Pharmaceuticals

Trius Therapeutics

TTY Biopharma

Unichem Laboratories

Valeant Pharmaceuticals

Vansen Pharma

ViroPharma

Warner Chilcott

Watson

Wockhardt

Zhejiang Medicine Company

Zuellig Pharma

Zydus Pharmaceuticals

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd